Download Free Sample Report

The global Amyotrophic Lateral Sclerosis Drugs market was valued at US$ 308.7 million in 2022 and is projected to reach US$ 359.5 million by 2029, at a CAGR of 2.2% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig?s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5?10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
This report aims to provide a comprehensive presentation of the global market for Amyotrophic Lateral Sclerosis Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Amyotrophic Lateral Sclerosis Drugs. This report contains market size and forecasts of Amyotrophic Lateral Sclerosis Drugs in global, including the following market information:

• Global Amyotrophic Lateral Sclerosis Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
• Global top five companies in 2022 (%)

GlobalAmyotrophic Lateral Sclerosis (ALS) Treatment key players include Mitsubishi Tanabe Pharma, Sanofi, etc. Global top two manufacturers hold a share over 80%.
North America is the largest market, with a share about 60%, followed by Japan, and Europe, both have a share over 20 percent.
In terms of product, Edaravone (Radicava) is the largest segment, with a share over 75%. And in terms of application, the largest application is Hospital, followed by Drugs Store, etc.
We surveyed the Amyotrophic Lateral Sclerosis Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Amyotrophic Lateral Sclerosis Drugs Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Amyotrophic Lateral Sclerosis Drugs Market Segment Percentages, by Type, 2022 (%)
Riluzole
Edaravone (Radicava)
CoQ10
Butylphthalide
Others
Global Amyotrophic Lateral Sclerosis Drugs Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Amyotrophic Lateral Sclerosis Drugs Market Segment Percentages, by Application, 2022 (%)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Amyotrophic Lateral Sclerosis Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Amyotrophic Lateral Sclerosis Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Amyotrophic Lateral Sclerosis Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Amyotrophic Lateral Sclerosis Drugs revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Sanofi
Mitsubishi Tanabe Pharma
Mylan
Apotex
Glemark Generics
Sun Pharma
Covis Pharma
Lunan Pharma
CSPC Pharmaceutical
Ascend Laboratories
EISAI
Outline of Major Chapters:
Chapter 1: Introduces the definition of Amyotrophic Lateral Sclerosis Drugs, market overview.
Chapter 2: Global Amyotrophic Lateral Sclerosis Drugs market size in revenue.
Chapter 3: Detailed analysis of Amyotrophic Lateral Sclerosis Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Amyotrophic Lateral Sclerosis Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.